Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria

Laura Diluvio; Arianna Piccolo; Francesco Marasco; Laura Vollono; Caterina Lanna; Barbara Chiaramonte; Cinzia Niolu; Elena Campione; Luca Bianchi

doi:10.2144/fsoa-2020-0087

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria

Future Sci OA. 2020 Aug 10;6(9):FSO618. doi: 10.2144/fsoa-2020-0087.

Authors

Laura Diluvio¹, Arianna Piccolo¹, Francesco Marasco², Laura Vollono¹, Caterina Lanna¹, Barbara Chiaramonte³, Cinzia Niolu², Elena Campione¹, Luca Bianchi¹

Affiliations

¹ Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, Rome 81 00133, Italy.
² Psychiatry, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, Rome 81 00133, Italy.
³ INAIL, Actuarial-Statistic consultancy office, via Stefano Gradi, Rome 55 00143, Italy.

Abstract

Background: Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab.

Materials & methods: A total of 30 patients were enrolled in the study: 15 patients affected by CSU and treated with omalizumab and the other 15 healthy subjects did not receive any systemic therapy. All patients were evaluated using Hospital Anxiety and Depression Scale, CRP and erythrocyte sedimentation rate, at baseline and after 6 months.

Results: The omalizumab group after 6 months of therapy had a decrease of all the scores and biomarkers.

Conclusion: Omalizumab allowed an improvement of urticaria and mental comorbidities.

Keywords: CSU; DLQI; H1-anti-histamine; HADS; Hospital Anxiety and Depression Scale; UAS7; anxiety; chronic spontaneous urticaria; depression; omalizumab; psychiatric disorders.